Molecular Imaging of Proteolytic Activity in Cancer

Journal of Cellular Biochemistry

Volumn 90, Issue 6, 2003, Pages 1087-1097

  McIntyre, J Oliver ^a   Matrisian, Lynn M ^a  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

MMP 7; Optical imaging; Proteinase

Indexed keywords

AMINO ACID COPOLYMER; CATHEPSIN B; CATHEPSIN K; COLLAGENASE 3; DENDRIMER; DISINTEGRIN; FLUORESCEIN; FLUORESCENT DYE; INTERSTITIAL COLLAGENASE; MATRILYSIN; MATRIX METALLOPROTEINASE; MATRIX METALLOPROTEINASE INHIBITOR; POLYLYSINE POLYETHYLENE GLYCOL COPOLYMER; POLYMER; PRINOMASTAT; PROTEASOME; PROTEASOME INHIBITOR; PROTEINASE; REGULATOR PROTEIN; STARBURST; STROMELYSIN; STROMELYSIN 3; THREONINE PROTEINASE; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNCLASSIFIED DRUG; UROKINASE;

ANGIOGENESIS; APOPTOSIS; AUTOFLUORESCENCE; BIOLUMINESCENCE; CANCER; CANCER DIAGNOSIS; CANCER GROWTH; CELL CYCLE; CLINICAL TRIAL; CONTRAST ENHANCEMENT; DIAGNOSTIC IMAGING; DIAGNOSTIC VALUE; ENZYME ACTIVATION; FIBROSARCOMA; FLUORESCENCE ANALYSIS; GASTROINTESTINAL POLYPOSIS; HOMEOSTASIS; HUMAN; METASTASIS; NEAR INFRARED FLUORESCENCE; NEOVASCULARIZATION (PATHOLOGY); NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROMOTER REGION; PROSTATE CANCER; PROTEIN DEGRADATION; PROTEIN TARGETING; REVIEW; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

ANIMALS; ANTINEOPLASTIC AGENTS; DIAGNOSTIC IMAGING; ENDOPEPTIDASES; HUMANS; MATRIX METALLOPROTEINASE 7; NEOPLASMS;

EID: 0344874727     PISSN: 07302312     EISSN: None     Source Type: Journal    
DOI: 10.1002/jcb.10713     Document Type: Review

References (88)

1. Adachi Y, Yamamoto H, Itoh F, Arimura Y, Nishi M, Endo T, Imai K. 2001. Clinicopathologic and prognostic significance of matrilysin expression at the invasive front in human colorectal cancers. Int J Cancer 95:290-294.
2. Balk SP, Ko YJ, Bubley GJ. 2003. Biology of prostate-specific antigen. J Clin Oncol 21:383-391.
3. Barrett AJ, Rawlings ND, Woessner JF, Jr. 1998. Handbook of proteolytic enzymes. London: Academic press.
4. Berger DH. 2002. Plasmin/plasminogen system in colorectal cancer. World J Surg 26:767-771.
5. Blasberg RG. 2003. Molecular imaging and cancer. Mol Cancer Ther 2:335-343.
6. Bogyo M, Wang EW. 2002. Proteasome inhibitors: Complex tools for a complex enzyme. Curr Top Microbiol Immunol 268:185-208.
7. Bremer C, Tung CH, Weissleder R. 2001. In vivo molecular target assessment of matrix metalloproteinase inhibition. Nat Med 7:743-748.
8. Bremer C, Tung CH, Bogdanov A, Jr., Weissleder R. 2002. Imaging of differential protease expression in breast cancers for detection of aggressive tumor phenotypes. Radiology 222(3):814-818.
9. Bremer C, Ntziachristos V, Weissleder R. 2003. Optical-based molecular imaging: Contrast agents and potential medical applications. Eur Radiol 13:231-243.
10. Brinckerhoff CE, Matrisian LM. 2002. Matrix metalloproteinases: A tail of a frog that became a prince. Nat Rev Mol Cell Biol 3:207-214.
11. Bromme D, Kaleta J. 2002. Thiol-dependent cathepsins: Pathophysiological implications and recent advances in inhibitor design. Curr Pharm Des 8:1639-1658.
12. Brown E, McKee T, diTomaso E, Pluen A, Seed B, Boucher Y, Jain RK. 2003. Dynamic imaging of collagen and its modulation in tumors in vivo using second-harmonic generation. Nat Med 9:796-800.
13. Chen WT, Kelly T. 2003. Seprase complexes in cellular invasiveness. Cancer Metastasis Rev 22:259-269.
14. Choyke PL, Dwyer AJ, Knopp MV. 2003. Functional tumor imaging with dynamic contrast-enhanced magnetic resonance imaging. J Magn Reson Imaging 17:509-520.
15. Corthals GL, Nelson PS. 2001. Large-scale proteomics and its future impact on medicine. Pharmacogenomics J 1:15-19.
16. Coussens LM, Fingleton B, Matrisian LM. 2002. Matrix metalloproteinase inhibitors and cancer: Trials and tribulations. Science 295:2387-2392.
17. Cusack JC. 2003. Rationale for the treatment of solid tumors with the proteasome inhibitor bortezomib. Cancer Treat Rev 29(Suppl 1):21-31.
18. Duffy MJ. 1996. Proteases as prognostic markers in cancer. Clin Cancer Res 2:613-618.
19. Duffy MJ. 2002. Urokinase plasminogen activator and its inhibitor, PAI-1, as prognostic markers in breast cancer: From pilot to level 1 evidence studies. Clin Chem 48:1194-1197.
20. Duffy MJ, Lynn DJ, Lloyd AT, O'Shea CM. 2003. The ADAMs family of proteins: From basic studies to potential clinical applications. Thromb Haemost 89:622-631.
21. Edinger M, Cao YA, Verneris MR, Bachmann MH, Contag CH, Negrin RS. 2003. Revealing lymphoma growth and the efficacy of immune cell therapies using in vivo bioluminescence imaging. Blood 101:640-648.
22. Evelhoch JL. 1999. Key factors in the acquisition of contrast kinetic data for oncology. J Magn Reson Imaging 10:254-259.
23. Fingleton B. 2003. Matrix metalloproteinase inhibitors for cancer therapy: The current situation and future prospects. Expert Opinion on Therapeutic Targets 7:385-397.
24. Friedl P, Wolf K. 2003. Tumour-cell invasion and migration: Diversity and escape mechanisms. Nat Rev Cancer 3:362-374.
25. Fuqua SA. 2001. The role of estrogen receptors in breast cancer metastasis. J Mammary Gland Biol Neoplasia 6:407-417.
26. Giambernardi TA, Grant GM, Taylor GP, Hay RJ, Maher VM, McCormick JJ, Klebe RJ. 1998. Overview of matrix metalloproteinase expression in cultured human cells. Matrix Biol 16:483-496.
27. Gillies RJ. 2003. Noninvasive imaging of anticancer therapy. Mol Cancer Ther 2:333-334.
28. Gore JC. 2003. Principles and practice of functional MRI of the human brain. J Clin Invest 112:4-9.
29. Goss KJ, Brown PD, Matrisian LM. 1998. Differing effects of endogenous and synthetic inhibitors of metalloproteinases on intestinal tumorigenesis. Int J Cancer 78:629-635.
30. Gross J, Lapiere CM. 1962. Collagenolytic activity in amphibian tissues: A tissue culture assay. Proc Acad Sci USA 48:1014-1022.
31. Gulsen G, Yu H, Wang J, Nalcioglu O, Merritt S, Bevilacqua F, Durkin AJ, Cuccia DJ, Lanning R, Tromberg BJ. 2002. Congruent MRI and near-infrared spectroscopy for functional and structural imaging of tumors. Technol Cancer Res Treat 1:497-505.
32. Harisinghani MG, Barentsz J, Hahn PF, Deserno WM, Tabatabaei S, van de Kaa CH, de la RJ, Weissleder R. 2003. Noninvasive detection of clinically occult lymphnode metastases in prostate cancer. N Engl J Med 348:2491-2499.
33. Herschman HR. 2003. Micro-PET imaging and small animal models of disease. Curr Opin Immunol 15:378-384.
34. Herszenyi L, Plebani M, Carraro P, De Paoli M, Roveroni G, Cardin R, Foschia F, Tulassay Z, Naccarato R, Farinati F. 2000. Proteases in gastrointestinal neoplastic diseases. Clin Chim Acta 291:171-187.
35. Hoffman JM. 2000. Imaging in cancer: A National Cancer Institute "extraordinary opportunity." Neoplasia 2:5-8.
36. Ivanov VN, Bhoumik A, Ronai Z. 2003. Death receptors and melanoma resistance to apoptosis. Oncogene 22:3152-3161.
37. Kiechle FL, Zhang X. 2002. Apoptosis: Biochemical aspects and clinical implications. Clin Chim Acta 326:27-45.
38. Koblinski JE, Ahram M, Sloane BF. 2000. Unraveling the role of proteases in cancer. Clin Chim Acta 291:113-135.
39. Laxman B, Hall DE, Bhojani MS, Hamstra DA, Chenevert TL, Ross BD, Rehemtulla A. 2002. Noninvasive real-time imaging of apoptosis. Proc Natl Acad Sci USA 99:16551-16555.
40. Lecaille F, Kaleta J, Bromme D. 2002. Human and parasitic papain-like cysteine proteases: Their role in physiology and pathology and recent developments in inhibitor design. Chem Rev 102:4459-4488.
41. Liotta LA, Tryggvason K, Garbisa S, Hart I, Foltz CM, Shafie S. 1980. Metastatic potential correlates with enzymatic degradation of basement membrane collagen. Nature 284:67-68.
42. Louie AY, Huber MM, Ahrens ET, Rothbacher U, Moats R, Jacobs RE, Fraser SE, Meade TJ. 2000. In vivo visualization of gene expression using magnetic resonance imaging. Nat Biotechnol 18:321-325.
43. MacDougall JR, Bani MR, Lin Y, Rak J, Kerbel RS. 1995. The 92-kDa gelatinase B is expressed by advanced stage melanoma cells: Suppression by somatic cell hybridization with early stage melanoma cell. Cancer Res 55:4174-4181.
44. Mahmood U, Weissleder R. 2003. Near-infrared optical imaging of proteases in cancer. Mol Cancer Ther 2:489-496.
45. Mandl S, Schimmelpfennig C, Edinger M, Negrin RS, Contag CH. 2002. Understanding immune cell trafficking patterns via in vivo bioluminescence imaging. J Cell Biochem Suppl 39:239-248.
46. Marten K, Bremer C, Khazaie K, Sameni M, Sloane B, Tung CH, Weissleder R. 2002. Detection of dysplastic intestinal adenomas using enzyme-sensing molecular beacons in mice. Gastroenterology 122:406-414.
47. McCawley LJ, Matrisian LM. 2001. Matrix metalloproteinases: They're not just for matrix anymore! Curr Opin Cell Biol 13:534-540.
48. McIntyre JO, Fingleton B, Wells KS, Piston DW, Lynch CC, Gautam S, Matrisian LM. 2003. Development of a novel fluorogenic proteolytic beacon for in vivo detection and imaging of tumor-associated matrix metalloproteinase-7 activity. Biochem J (in press).
49. Narula J, Acio ER, Narula N, Samuels LE, Fyfe B, Wood D, Fitzpatrick JM, Raghunath PN, Tomaszewski JE, Kelly C, Steinmetz N, Green A, Tait JF, Leppo J, Blankenberg FG, Jain D, Strauss HW. 2001. Annexin-V imaging for noninvasive detection of cardiac allograft rejection. Nat Med 7:1347-1352.
50. Nelson SJ. 2003. Multivoxel magnetic resonance spectroscopy of brain tumors. Mol Cancer Ther 2:497-507.
51. Nelson AR, Fingleton B, Rothenberg ML, Matrisian LM. 2000. Matrix metalloproteinases: Biologic activity and clinical implications. J Clin Oncol 18:1135-1149.
52. Netzel-Arnett S, Hooper JD, Szabo R, Madison EL, Quigley JP, Bugge TH, Antalis TM. 2003. Membrane anchored serine proteases: A rapidly expanding group of cell surface proteolytic enzymes with potential roles in cancer. Cancer Metastasis Rev 22:237-258.
53. Newell KJ, Witty JP, Rodgers WH, Matrisian LM. 1994. Expression and localization of matrix-degrading metalloproteinases during colorectal tumorigenesis. Mol Carcinog 10:199-206.
54. Nijziel MR, Van Oerle R, Hellenbrand D, Van Pampus EC, Hillen HF, Hamulyak K. 2003. The prognostic value of the soluble urokinase-type plasminogen activator receptor (s-uPAR) in plasma of breast cancer patients with and without metastatic disease. J Thromb Haemost 1:982-986.
55. Pasricha PJ, Motamedi M. 2002. Optical biopsies, " bioendoscopy," and why the sky is blue: The coming revolution in gastrointestinal imaging. Gastroenterology 122:571-575.
56. Petrovsky A, Schellenberger E, Josephson L, Weissleder R, Bogdanov A, Jr. 2003. Near-infrared fluorescent imaging of tumor apoptosis. Cancer Res 63:1936-1942.
57. Raghunand N, Howison C, Sherry AD, Zhang S, Gillies RJ. 2003. Renal and systemic pH imaging by contrast-enhanced MRI. Magn Reson Med 49:249-257.
58. Rawlings ND, O'Brien E, Barrett AJ. 2002. MEROPS: The protease database. Nucleic Acids Res 30:343-346.
59. Ritman EL. 2002. Molecular imaging in small animals-roles for micro-CT. J Cell Biochem Suppl 39:116-124.
60. Rochefort H, Garcia M, Glondu M, Laurent V, Liaudet E, Rey JM, Roger P. 2000. Cathepsin D in breast cancer: Mechanisms and clinical applications, a 1999 overview. Clin Chim Acta 291:157-170.
61. Roshy S, Sloane BF, Moin K. 2003. Pericellular cathepsin B and malignant progression. Cancer Metastasis Rev 22:271-286.
62. Ross BD, Moffat BA, Lawrence TS, Mukherji SK, Gebarski SS, Quint DJ, Johnson TD, Junck L, Robertson PL, Muraszko KM, Dong Q, Meyer CR, Bland PH, McConville P, Geng H, Rehemtulla A, Chenevert TL. 2003. Evaluation of cancer therapy using diffusion magnetic resonance imaging. Mol Cancer Ther 2:581-587.
63. Rossi D, Gaidano G. 2003. Messengers of cell death: Apoptotic signaling in health and disease. Haematologica 88:212-218.
64. Rossi S, Loda M. 2002. The role of the ubiquitination-proteasome pathway in breast cancer: Use of mouse models for analyzing ubiquitination processes. Breast Cancer Res 5:16-22.
65. Rowland DJ, Lewis JS, Welch MJ. 2002. Molecular imaging: The application of small animal positron emission tomography. J Cell Biochem Suppl 39:110-115.
66. Rudolph-Owen LA, Chan R, Muller WJ, Matrisian LM. 1998. The matrix metalloproteinase matrilysin influences early-stage mammary tumorigenesis. Cancer Res 58:5500-5506.
67. Salvesen GS. 2002. Caspases and apoptosis. Essays Biochem 38:9-19.
68. Seals DF, Courtneidge SA. 2003. The ADAMs family of metalloproteases: Multidomain proteins with multiple functions. Gen Dev 17:7-30.
69. Smith PW. 2002. Fluorescence emission-based detection and diagnosis of malignancy. J Cell Biochem Suppl 39:54-59.
70. Somerville RP, Longpre JM, Jungers KA, Engle JM, Ross M, Evanko S, Wight TN, Leduc R, Apte SS. 2003a. Characterization of ADAMTS-9 and ADAMTS-20 as a distinct ADAMTS subfamily related to Caenorhabditis elegans GON-1. J.Biol Chem 278:9503-9513.
71. Somerville RP, Oblander SA, Apte SS. 2003b. Matrix metalloproteinases: Old dogs with new tricks. Genome Biol 4:216.
72. Speirs V. 2002. Oestrogen receptor beta in breast cancer: Good, bad, or still too early to tell? J Pathol 197:143-147.
73. Sternlicht MD, Bergers G. 2000. Matrix metalloproteinases as emerging targets in anticancer therapy: Status and prospects. Emerging Therapeutic Targets 4:609-633.
74. Weissleder R. 2001. A clearer vision for in vivo imaging. Nat Biotechnol 19:316-317.
75. Weissleder R. 2002. Scaling down imaging: Molecular mapping of cancer in mice. National Review of Cancer 2:11-18.
76. Weissleder R, Mahmood U. 2001. Molecular imaging. Radiology 219:316-333.
77. Weissleder R, Tung H, Mahmood U, Bogdanov A, Jr. 1999. In vivo imaging of tumors with protease-activated near-infrared fluorescent probes. Nat Biotechnol 17:375-378.
78. Wilson CL, Matrisian LM. 1998. Matrilysin. In: Parks WC, Mecham RP, editors. Matrix metalloproteinases. San Diego: Academic Press. pp 149-184.
79. Wilson CL, Heppner KJ, Labosky PA, Hogan BLM, Matrisian LM. 1997. Intestinal tumorigenesis is suppressed in mice lacking the metalloproteinase matrilysin. Proc Acad Sci USA 94:1402-1407.
80. Woessner JF, Nagase H. 2000. Matrix metalloproteinases and TIMPs. New York: Oxford University Press, Inc.
81. Wolf C, Rouyer N, Lutz Y, Adida C, Loriot M, Bellocq JP, Chambon P, Basset P. 1993. Stromelysin 3 belongs to a subgroup of proteinases expressed in breast carcinoma fibroblastic cells and possibly implicated in tumor progression. Proc Acad Sci USA 90:1843-1847.
82. Wolf K, Mazo I, Leung H, Engelke K, Von Andrian UH, Deryugina EI, Strongin AY, Brocker EB, Friedl P. 2003. Compensation mechanism in tumor cell migration: Mesenchymal-amoeboid transition after blocking of pericellular proteolysis. J Cell Biol 160:267-277.
83. Wu N, Opalenik S, Liu J, Jansen ED, Giro MG, Davidson JM. 2002. Real-time visualization of MMP-13 promoter activity in transgenic mice. Matrix Biol 21:149-161.
84. Yamamoto H, Adachi Y, Itoh F, Iku S, Matsuno K, Kusano M, Arimura Y, Endo T, Hinoda Y, Hosokawa M, Imai K. 1999. Association of matrilysin expression with recurrence and poor prognosis in human esophageal squamous cell carcinoma. Cancer Res 59:3313-3316.
85. Yamamoto H, Itoh F, Iku S, Adachci Y, Fukushima H, Sasaki S, Mukaiya M, Hirata K, Imai K. 2001. Expression of matrix metalloproteinases and tissue inhibitors of metalloproteinases in human pancreatic adenocarcinomas: Clinicopathologic and prognostic significance of matrilysin expression. J Clin Oncol 19:1118-1127.
86. Zhang J, Campbell RE, Ting AY, Tsien RY. 2002. Creating new fluorescent probes for cell biology. Nat Rev Mol Cell Biol 3:906-918.
87. Zhao M, Josephson L, Tang Y, Weissleder R. 2003. Magnetic sensors for protease assays. Angew Chem Int Ed Engl 42:1375-1378.
88. Zoumi A, Yeh A, Tromberg BJ. 2002. Imaging cells and extracellular matrix in vivo by using second-harmonic generation and two-photon excited fluorescence. Proc Natl Acad Sci USA 99:11014-11019.